AFJK vs CLOV

Aimei Health Technology Co.

, Ltd (AFJK) offers the better valuation at 251. 0x trailing P/E, making it the more compelling value choice. Analysts rate Clover Health Investments, Corp. (CLOV) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aimei Health Technology Co.

, Ltd (AFJK) delivered a total return of +320. 4%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: AFJK returned +320. 4% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aimei Health Technology Co.

, Ltd (AFJK) is the lower-risk stock at 0. 23β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 423% more volatile than AFJK relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Aimei Health Technology Co.

, Ltd grew EPS -39. 3% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aimei Health Technology Co.

, Ltd (AFJK) is the more profitable company, earning 0. 0% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AFJK leads at 0. 0% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aimei Health Technology Co.

, Ltd (AFJK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +320. 4% 10Y return). Both have compounded well over 10 years (AFJK: +320. 4%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AFJK (Financial Services) and CLOV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AFJK is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.